Because of the manufacturer’s decision, Numan may need to raise prices. We’ll let you know about any changes in advance.
What you need to know
From 1st September, the manufacturer of Mounjaro will be increasing its prices. We know this change may feel concerning but, rest assured, your health and progress are our top priority. We’ll be here to provide clarity, guidance, and support at every stage.
Here’s what the change means:
Whenever there are price changes, you’ll always be able to review your subscription and request to change your treatment plan.
This change only affects Mounjaro. Other weight loss medications, including Wegovy and Alli, are currently unaffected and can be considered as alternative treatment options.
The difference between Mounjaro and Wegovy
If you feel your treatment isn’t quite right, and the price changes are concerning you, our clinicians can assess your case and help you switch to a suitable alternative. Below is a summary of key differences between the GLP-1 medications.
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Mechanism of action | Mimics the actions of GIP and GLP-1, hormones that help regulate appetite and blood sugar levels. | Mimics the action of GLP-1, a hormone that helps regulate appetite. |
| Condition treated | Obesity | Obesity and reduced cardiovascular risk¹ |
| Injection frequency | Once weekly | Once weekly |
| Achievable weight loss, according to research | Up to 22.5%² | Up to 17.5%³ |
What to do if you want to stay on Mounjaro
The manufacturer of Mounjaro is increasing prices by up to 170%. While Numan will not raise prices to this level, there may be a need for some increase. Wegovy is a more cost-effective treatment, but if you’d prefer to stay on Mounjaro, you still have several options:
Along with any price increases, you can continue your treatment and pay the new price. If this is your preference, you do not need to do anything and the new price will be updated on your subscription with advanced notice.
You may see effective weight loss on a lower dose which, depending on the dose, could be a more affordable option for you.
If you decide you’d prefer a more cost-effective solution, you can easily switch to Wegovy following clinical approval.
How to request a change of medication
Wegovy is another proven treatment for weight loss and if you want to switch, we’ll always aim to make the transition as fast and smooth as possible. Clinical approval is needed, and demand may cause delays, but we’ll do everything we can to keep your treatment on track.
Step one
Submit a request in the app, or complete the online consultation if you’re new to Numan.
Step two
A clinician will assess your medical background and preferences to determine if Wegovy is appropriate.
Step three
If approved, your treatment will be delivered along with clear guidance on transitioning from your current medication.
Latest Wegovy research
Since its UK launch in 2023, ongoing research into Wegovy has led to new developments. In 2024, it received approval for use in reducing the risk of cardiovascular events in people with cardiovascular disease.4
On top of this, new trial data, published in June 2025, suggests higher doses of semaglutide, the active ingredient in Wegovy, can deliver increased weight loss results.5
The Numan Programme
Numan’s Weight Loss Programme pairs clinically-proven medication with one-to-one health coaching. We reject outdated diet culture and patient blame, focusing on modern, effective solutions. With the programme, you’ll receive:
Ongoing clinical care whenever it’s needed
One-to-one support from a health coach to navigate challenges and celebrate wins
Evidence-based guidance to help you understand your body and protect your health
Support when you need it
If you’re still concerned about the ongoing changes, don’t hesitate to reach out to our Customer Care Team. We’re here to help, answer your questions, and guide you through any concerns every step of the way.
FAQS
Your questions answered
KNOWLEDGE
Learn more about our weight loss treatments
/ "Eva")
References
1 Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England journal of medicine. 2023;389(24): 2221–2232.
2Ard J, Lee CJ, Gudzune K, Addison B, Lingvay I, Cao D, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-Diabetes, obesity & metabolism. 2025;27(9): 5064–5071.
3 Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial: The STEP 4 randomized clinical trial. JAMA: the journal of the American Medical Association. 2021;325(14): 1414–1425.
4 Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England journal of medicine. 2023;389(24): 2221–2232.
5 Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17.
Start your treatment journey
Answer a few simple questions to get the treatment you need.